A detailed history of Rock Springs Capital Management LP transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 3,681,174 shares of INZY stock, worth $17.7 Million. This represents 0.74% of its overall portfolio holdings.

Number of Shares
3,681,174
Previous 3,681,174 -0.0%
Holding current value
$17.7 Million
Previous $15.7 Million 79.82%
% of portfolio
0.74%
Previous 0.39%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $1.04 Million - $1.77 Million
253,090 Added 7.38%
3,681,174 $15.5 Million
Q2 2023

Aug 14, 2023

BUY
$4.93 - $6.74 $1.05 Million - $1.44 Million
213,184 Added 6.63%
3,428,084 $19.1 Million
Q1 2023

May 15, 2023

BUY
$1.3 - $5.73 $167,534 - $738,442
128,873 Added 4.18%
3,214,900 $18.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.05 - $1.8 $292,329 - $501,136
278,409 Added 9.92%
3,086,027 $3.24 Million
Q3 2022

Nov 14, 2022

BUY
$2.62 - $5.45 $439,012 - $913,212
167,562 Added 6.35%
2,807,618 $7.52 Million
Q2 2022

Aug 15, 2022

BUY
$3.2 - $5.96 $4.63 Million - $8.62 Million
1,446,861 Added 121.26%
2,640,056 $12.6 Million
Q1 2022

May 16, 2022

BUY
$3.87 - $7.55 $1.26 Million - $2.45 Million
324,729 Added 37.39%
1,193,195 $4.88 Million
Q4 2021

Feb 14, 2022

BUY
$5.58 - $11.5 $102,956 - $212,186
18,451 Added 2.17%
868,466 $5.92 Million
Q3 2021

Nov 15, 2021

BUY
$11.12 - $19.4 $108,342 - $189,014
9,743 Added 1.16%
850,015 $9.85 Million
Q2 2021

Aug 16, 2021

BUY
$15.19 - $21.2 $187,930 - $262,286
12,372 Added 1.49%
840,272 $14.3 Million
Q1 2021

May 17, 2021

SELL
$17.77 - $27.9 $47,019 - $73,823
-2,646 Reduced 0.32%
827,900 $16.4 Million
Q4 2020

Feb 16, 2021

SELL
$19.95 - $27.55 $985,689 - $1.36 Million
-49,408 Reduced 5.61%
830,546 $17.1 Million
Q3 2020

Nov 16, 2020

BUY
$17.54 - $30.2 $15.4 Million - $26.6 Million
879,954 New
879,954 $23.1 Million

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $194M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.